Trial · NCT04902105
Drug-Drug Interaction Study to Evaluate the Effect of Inhibition of UGTs on the PK of Ecopipam and Its Active Metabolite
NCT04902105, Phase 1, Completed, Emalex Biosciences Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Drug-Drug Interaction Study to Evaluate the Effect of Inhibition of UGTs on the PK of Ecopipam and Its Active Metabolite. Trials, record NCT04902105. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04902105
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Drug-Drug Interaction Study to Evaluate the Effect of Inhibition of UGTs on the PK of Ecopipam and Its Active Metabolite
- NCT number
- NCT04902105
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 38 participants, actual
- Lead sponsor
- Emalex Biosciences Inc.
- Conditions
- Drug Interaction
- Interventions
- ecopipam HCL, Mefenamic acid, Divalproex Sodium ER
- First posted
- 2021-05-26
- Last updated
- 2021-07-22
Source ClinicalTrials.gov
Registered outcomes75
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Cmax of ecopipam in the presence of mefenamic acid | Up to Day 16 | Up to 35 blood samples will be collected at the indicated time points for pharmacokinetic analysis |
| Primary | Cmax of ecopipam in the absence of mefenamic acid | Up to Day 16 | Up to 35 blood samples will be collected at the indicated time points for pharmacokinetic analysis |
| Primary | Cmax of ecopipam in the presence of divalproex sodium ER | Up to Day 16 | Up to 35 blood samples will be collected at the indicated time points for pharmacokinetic analysis |
| Primary | Cmax of ecopipam in the absence of divalproex sodium ER | Up to Day 16 | Up to 35 blood samples will be collected at the indicated time points for pharmacokinetic analysis |
| Primary | AUCinf of ecopipam in the presence of mefenamic acid | Up to Day 16 | Up to 35 blood samples will be collected at the indicated time points for pharmacokinetic analysis |
| Primary | AUCinf of ecopipam in the absence of mefenamic acid | Up to Day 16 | Up to 35 blood samples will be collected at the indicated time points for pharmacokinetic analysis |
| Primary | AUCinf of ecopipam in the presence of divalproex sodium ER | Up to Day 16 | Up to 35 blood samples will be collected at the indicated time points for pharmacokinetic analysis |
| Primary | AUCinf of ecopipam in the absence of divalproex sodium ER | Up to Day 16 | Up to 35 blood samples will be collected at the indicated time points for pharmacokinetic analysis |
| Primary | AUC0-143 of ecopipam in the presence of mefenamic acid | Up to Day 16 | Up to 35 blood samples will be collected at the indicated time points for pharmacokinetic analysis |
| Primary | AUC0-143 of ecopipam in the absence of mefenamic acid | Up to Day 16 | Up to 35 blood samples will be collected at the indicated time points for pharmacokinetic analysis |
1 to 10 of 75Source ClinicalTrials.gov
See all 75 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04902105
GET https://conductscience.org/api/trials/v1/NCT04902105/registered?page=2